A Phase 1 interventional study of MWN105 1 and MWN105 2 in Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM) and MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Obesity by Lepu Medical — 6 open to participants now, 8 under way, 1 of them phase 3. Obesity · Lepu Medical.
Among the 14 studies in Obesity by Lepu Medical, this one is the 14th largest by planned enrollment, is one of 7 that started in 2026, is one of 8 in phase 1, and was the 12th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →6 of the 14 studies in Obesity by Lepu Medical are open now, in 2 countries. Recruiting first, the newest first:
Shanghai Minwei Biotechnology Co., Ltd · Sites in Australia
Ages 18–60 · Healthy volunteers
Shanghai Minwei Biotechnology Co., Ltd · Sites in Australia
Ages 18–50 · Healthy volunteers
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–55 · Healthy volunteers
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–65
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 7 started in 2026.
This study's planned enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 88 across the 14 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shanghai Minwei Biotechnology Co., Ltd, one of the names counted as Lepu Medical. Under that name alone:
Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.
3 of the studies in Obesity by Lepu Medical that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07778693Phase 3Shanghai Minwei Biotechnology Co., LtdPhase 3 Study of MWN109 Injection in Participants With Overweight or Obesity | 2027-09 |
| NCT07779980Shanghai Minwei Biotechnology Co., LtdPhase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants | 2027-08 |
| NCT07824804Shanghai Minwei Biotechnology Co., LtdPhase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Obesity by Lepu Medical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN105 injection in Chinese non-diabetic overweight or obese participants.
The study plans to enroll 36 male and female participants. Three dose groups were preset, with 12 participants in each. They were randomly assigned to receive MWN105 injection or placebo at a ratio of 5:1 and were administered the treatment in a titration manner, once a week, with a dose increase every two weeks until reaching the target dose. The administration lasted for 8 weeks.
The study consists of a 2-week screening period, an 8-week administration/observation period, and a 4-week follow-up period, totaling 14 weeks. The primary endpoint is the incidence of adverse events. Secondary endpoints include pharmacokinetics, pharmacodynamics, and immunogenicity.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.
First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals with a history or evidence of any of the following:
Use of any of the following medications or treatments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MWN105 1 · Drug: Placebo
Drug: MWN105 2 · Drug: Placebo
Drug: MWN105 3 · Drug: Placebo
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Safety and tolerability assessed by the incidence of AEs and SAEs.
Time frame: From Day 1 to Day 78
Maximum Concentration (Cmax)
Cmax of MWN105.
Time frame: From Day 1 to Day 78
Time to Reach Maximum Concentration (Tmax)
Tmax of MWN105.
Time frame: From Day 1 to Day 78
Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)
AUC0-t of MWN105.
Time frame: From Day 1 to Day 78
Area Under the Curve From Time 0 to Infinity (AUC0-inf)
AUC0-inf of MWN105.
Time frame: From Day 1 to Day 78
Elimination Half-Life (t1/2)
t1/2 of MWN105.
Time frame: From Day 1 to Day 78
Change from baseline in body weight over time
Change in body weight from baseline to Day 78.
Time frame: Baseline, Day 78
Change from baseline in body mass index (BMI) over time
Change in BMI from baseline to Day 78.
Time frame: Baseline, Day 78
Change from baseline in waist circumference over time
Change in waist circumference from baseline to Day 78.
Time frame: Baseline, Day 78
Change from baseline in lipid profile over time
Change in lipid parameters (including total cholesterol, LDL-C, HDL-C, triglycerides) from baseline to Day 78.
Time frame: Baseline, Day 78
Detect anti-drug antibodies (ADA)
Time frame: Baseline, Day 78
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 6 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MWN105
Shanghai Minwei Biotechnology Co., Ltd →